How much should investors expect sales of Keytruda, the best-selling drug in the world, to decline in the coming years? And can they trust Merck’s guidance on that decline? The problems with ...

(RTTNews) - Merck (MRK) announced that Health Canada has granted approval for KEYTRUDA, Merck's anti-PD-1 therapy, as a treatment for adult patients with resectable Stage II, IIIA, or IIIB non ...

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...

The firm initially upgraded the stock in early 2024, expecting a strong performance from Keytruda and Gardasil, a lack of major risks, and management’s efforts to extend Keytruda’s outlook.

Keytruda and Lenvima with chemotherapy improved progression-free survival and objective response rate but not overall survival in HER2-negative gastroesophageal adenocarcinoma. The safety profile of ...

Keytruda market Insights: Continued dominance as a leading immunotherapy drug for multiple cancers, with expanding indications. US, NY, UNITED STATES, January 20, 2025 /EINPresswire / -- Market ...

Adagene (ADAG) announced updated clinical data from ADG126 in microsatellite stable colorectal cancer, MSS CRC, at the ASCO Gastrointestinal Cancers Symposium in San Francisco, CA. This Phase 1b/2 ...

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial.

Immune checkpoint inhibitors have been the MVP of cancer drugs in recent years. Merck’s Keytruda, for example, has been used against dozens of different cancers in millions of patients ...

MSD’s Keytruda initially gained approval in Canada in 2015. Credit: JHVEPhoto/Shutterstock. Health Canada has approved MSD’s anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating ...

Keytruda remains Merck's top-selling product and still comprises a significant portion of the company's overall revenue, bringing in $7.84 billion in sales in Q4 2024, up 19 percent from $6.61 billion ...